Understanding failure in targeted breast cancer therapy
21 Jul 2015
Understanding failure in targeted breast cancer therapy
De-activating chromosomes to prevent cancer
Banking on biomarkers – improving the diagnosis of early stage NSCLC
WIN Symposium 2015 highlights
Next generation of trials with targeted agents
The importance of target expression in personalised medicine
Taking biopsies in clinical trials: The WINTHER laboratory experience
Meta-analysis confirms benefits and safety of precision medicine
SPECTAlung: improving clinical trial access for patients with thoracic tumours
Biomarkers for childhood relapsed acute lymphoblastic leukaemia
Exciting new developments in proton therapy treatments
PDL1 expression in thymic tumours